tiprankstipranks
NLS Pharmaceutics Advances DOXA Platform Amid Merger Plans
Company Announcements

NLS Pharmaceutics Advances DOXA Platform Amid Merger Plans

Story Highlights

Pick the best stocks and maximize your portfolio:

NLS Pharmaceutics ( (NLSP) ) just unveiled an update.

NLS Pharmaceutics announced substantial progress in its Dual Orexin Receptor Agonist (DOXA) platform for treating sleep and neurodegenerative diseases, with promising results from preclinical studies on compounds AEX-41 and AEX-2. The company is also preparing for a transformative merger with Kadimastem Ltd., which will enhance its development pipeline and financial position, while ensuring compliance with Nasdaq listing requirements and strengthening its balance sheet through financial restructuring and private placements.

More about NLS Pharmaceutics

NLS Pharmaceutics Ltd. is a global development-stage biopharmaceutical company based in Switzerland, founded in 2015. It focuses on discovering and developing innovative therapies for rare and complex central nervous system disorders, working with world-class partners and scientists.

YTD Price Performance: -91.61%

Average Trading Volume: 305,714

Technical Sentiment Consensus Rating: Buy

Current Market Cap: $4.9M

For an in-depth examination of NLSP stock, go to TipRanks’ Stock Analysis page.

Related Articles
TheFlyNLS Pharmaceutics expects to close Kadimastem merger by end of January
TipRanks Auto-Generated NewsdeskNLS Pharmaceutics Offers New Investment Opportunities
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App